Remicade, Gilenya income boost Mitsubishi Tanabe's 2Q profit
This article was originally published in Scrip
Remicade (infliximab) contributed to Mitsubishi Tanabe Pharma's (MTP) results for the second quarter ended 30 September in more ways than one. Not only is the anti-TNF antibody the Japanese firm's top-selling product, a $117m arbitration settlement with licensor Janssen earlier this year also provided a healthy fillip to its net profit.
You may also be interested in...
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.